Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.60 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.50 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.43 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.43 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
| ▸ | PLG | P00747 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | PLAT | P00750 | 1/20 | 0.40 |
| ▸ | CPS1 | P31327 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4090389 | 0.98 | DGAT1 (0.58) | DGAT1MAP2K2MAP2K1LOXL2PARP1 | |
| Hydrochloric Acid SCHEMBL4090387 | 0.96 | DGAT1 (0.56) | DGAT1MAP2K2MAP2K1LOXL2PARP1 | |
| Trifluoroacetic Acid SCHEMBL29693047 | 0.89 | DGAT1 (0.50) | DGAT1MAP2K2MAP2K1LOXL2PARP1 | |
| SCHEMBL1478262 | 0.88 | MAP2K2 (0.50) | DGAT1MAP2K2MAP2K1LOXL2PARP1 | |
| Hydrochloric Acid SCHEMBL28268305 | 0.86 | MAP2K2 (0.49) | DGAT1MAP2K2MAP2K1LOXL2PARP1 | |
| SCHEMBL9726681 | 0.83 | CSNK2A1 (0.47) | DGAT1MAP2K2MAP2K1LOXL2CSNK2A1 | |
| SCHEMBL489010 | 0.81 | CSNK2A1 (0.61) | LOXL2CSNK2A1 | |
| SCHEMBL29688899 | 0.81 | KMT2A (0.46) | LOXL2CSNK2A1CES2CES1CPS1 | |
| SCHEMBL1226712 | 0.81 | KMT2A (0.46) | LOXL2CSNK2A1CES2CES1CPS1 | |
| SCHEMBL24311296 | 0.79 | PARP1 (0.44) | MAP2K2MAP2K1PARP1CSNK2A1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138969-A1 | TRIAZOLE COMPOUND HAVING NOVEL RING STRUCTURE, METHOD FOR PREPARING SAME, AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2026-05-21 | — | — | US | claimed |
| EP-4745133-A1 | TRIAZOLE COMPOUND HAVING NOVEL RING STRUCTURE, METHOD FOR PREPARING SAME, AND USE THEREOF | Korea Research Institute of Chemical Technology (KR) | 2026-05-20 | — | — | EP | claimed |
| CN-115279759-A | 3- ((8- ((1H-pyrazol-4-yl) amino) imidazo [1,2-a ] pyridin-3-yl) ethynyl) -N-phenylbenzamide derivative, preparation method thereof, and pharmaceutical composition for preventing or treating cancer containing same as active ingredient | 大邱庆北尖端医疗产业振兴财团 | 2022-11-01 | — | — | CN | claimed |
| WO-2022149855-A1 | HETEROARYL-ETHYNYL DERIVATIVE COMPOUND AND USE THEREOF | 주식회사 비투에스바이오 | 2022-07-14 | — | — | WO | claimed |
| EP-3448850-B1 | PIPERIDINYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2020-11-04 | — | — | EP | claimed |
| US-10428024-B2 | Piperidinyl derivatives | MERCK PATENT GMBH (DE) | 2019-10-01 | — | — | US | claimed |
| US-20190135753-A1 | PIPERIDINYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2019-05-09 | — | — | US | claimed |
| CN-105209429-B | SHIP1 conditioning agents and relative method | 阿奎诺克斯药物（加拿大）公司 | 2018-05-29 | — | — | CN | claimed |
| EP-2906559-B1 | AZAINDOLINES | HOFFMANN LA ROCHE (CH) | 2017-02-08 | — | — | EP | claimed |
| US-9309248-B2 | Azaindolines | HOFFMANN-LA ROCHE INC. (US) | 2016-04-12 | — | — | US | claimed |
| US-20100056460-A1 | COMBINATION OF ORGANIC COMPOUNDS | ALI MOHAMMED A | 2010-03-04 | — | — | US | claimed |
| US-20090131447-A1 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2009-05-21 | — | — | US | claimed |
| EP-1907004-A2 | COMBINATION OF A RENIN INHIBITOR AND AN INSULIN SECRETION ENHANCER OR AN INSULIN SENSITIZER | Novartis AG (CH) | 2008-04-09 | — | — | EP | claimed |
| US-7335658-B2 | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2008-02-26 | — | — | US | claimed |
| EP-1846035-A2 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2007-10-24 | — | — | EP | claimed |
| WO-2007005763-A2 | COMBINATION OF A RENIN INHIBITOR AND AN INSULIN SECRETION ENHANCER OR AN INSULIN SENSITIZER | NOVARTIS AG (CH) | 2007-01-11 | — | — | WO | claimed |
| WO-2006086445-A2 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2006-08-17 | — | — | WO | claimed |
| US-20050065143-A1 | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2005-03-24 | — | — | US | claimed |
| US-20040110778-A1 | Heterocyclic compounds as ligands of the GABAA receptor | YOHANNES DANIEL (US) | 2004-06-10 | — | — | US | claimed |
| US-20030105081-A1 | Heterocyclic compounds as ligands of the GABAA receptor | PFIZER INC | 2003-06-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105081-A1 | Heterocyclic compounds as ligands of the GABAA receptor | GABRB1, GABRP, GABRA1 | DGAT1 3070/4885MAP2K2 3635/4885MAP2K1 4071/4885 |
| US-20050065143-A1 | Pyridazine derivatives and their use as therapeutic agents | PRDX5, SNRPD3, SNRPD2 | DGAT1 4434/4885MAP2K2 4681/4885MAP2K1 4826/4885 |
| US-20260138969-A1 | TRIAZOLE COMPOUND HAVING NOVEL RING STRUCTURE, METHOD FOR PREPARING SAME, AND USE THEREOF | CASP1, CASP3, BAD | DGAT1 834/4885MAP2K2 69/4885MAP2K1 49/4885 |
| US-10428024-B2 | Piperidinyl derivatives | PDK1, PDK2, PDK3 | DGAT1 2156/4885MAP2K2 1076/4885MAP2K1 1140/4885 |
| US-20190135753-A1 | PIPERIDINYL DERIVATIVES | PDK1, PDK2, PDK3 | DGAT1 2156/4885MAP2K2 1076/4885MAP2K1 1140/4885 |
| US-20040110778-A1 | Heterocyclic compounds as ligands of the GABAA receptor | GABRB1, GABRP, GABRA1 | DGAT1 3070/4885MAP2K2 3635/4885MAP2K1 4071/4885 |
| US-20100056460-A1 | COMBINATION OF ORGANIC COMPOUNDS | REN, IAPP, ACE | DGAT1 1163/4885MAP2K2 1104/4885MAP2K1 658/4885 |
| US-20090131447-A1 | COMBINATION THERAPY | SCD, SCD5, ARG1 | DGAT1 1025/4885MAP2K2 3694/4885MAP2K1 3523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.